Cervical Cancer

BASHH Expresses Disappointment That The Government Missed The Chance To Eradicate Genital Warts From The Medical Map
The British Association for Sexual Health and HIV (BASHH) today expressed disappointment that the Government has missed the opportunity to eradicate a common STI, genital warts, from the medical map, as today's announcement by the Department of Health on the human papillomavirus vaccine (HPV), "Department of Health awards contract for HPV vaccine", saw GlaxoSmithKline's vaccine Ceravix awarded the Government contract.

University Of Iowa To Begin Using LUMA(R) Cervical Pre Cancer Imaging Device
SpectraScience, Inc. (OTC Bulletin Board: SCIE), a San Diego-based medical devices company, announced that it has placed its LUMA Cervical Imaging System to detect pre-cancers at the University of Iowa in Iowa City, Iowa under the direction of Dr. Colleen Kennedy. Dr.

GlaxoSmithKline Responds To FDA On Cervarix� And Plans To Submit Final Study Data For Approval
GlaxoSmithKline provided the following update regarding its application to the U.S. Food and Drug Administration (FDA) for approval of Cervarix�, its vaccine to prevent cervical cancer. GSK has submitted its response to questions raised by the FDA in their Complete Response Letter, received in December, 2007.

Merck Responds To Questions About Adverse Events Reported Following Vaccination With GARDASIL�
Merck issued the following statement to address questions about adverse events reported in people who had received GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine, Recombinant]. Merck has analyzed the adverse events reported for GARDASIL relating to the recent reports of death and paralysis, and based on the data available to Merck, believes that no safety issue related to the vaccine has been identified.

Merck Responds To Questions About Adverse Events Reported Following Vaccination With GARDASIL�
Merck issued the following statement to address questions about adverse events reported in people who had received GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine, Recombinant]. Merck has analyzed the adverse events reported for GARDASIL relating to the recent reports of death and paralysis, and based on the data available to Merck, believes that no safety issue related to the vaccine has been identified.

FDA Delays Approval Of Mercks HPV Vaccine Gardasil For Older Women
FDA has delayed a decision on Merck's application to expand marketing of its human papillomavirus vaccine Gardasil to women ages 27 to 45, the company said Wednesday, the Newark Star-Ledger reports (Newark Star-Ledger, 6/26).

Gen-Probe Launches In Europe CE-Marked APTIMA(R) HPV Assay For Detection Of Human Papillomavirus
Gen-Probe Incorporated (Nasdaq: GPRO) announced that the Company has launched in Europe its APTIMA(R) HPV Assay, a highly specific molecular diagnostic test to detect high-risk strains of the human papillomavirus (HPV), which causes cervical cancer. The APTIMA HPV Assay has been CE marked and is currently available for sale in 13 European Union countries.

GSK Awarded Three-Year Contract To Supply British Government With HPV Vaccine Cervarix
GlaxoSmithKline announced on Wednesday that it has received a three-year contract from the United Kingdom's Department of Health to supply the country's immunization program with its human papillomavirus vaccine Cervarix, the Wall Street Journal reports. The health department's goal is to vaccinate all girls ages 12 to 13 with Cervarix to protect against cervical cancer. GSK will sell Cervarix, administered in a three-shot series, to the state health system.

VGX Pharmaceuticals Receives FDA Approval Of IND For Novel DNA Vaccine For Cervical Cancer Therapy
VGX Pharmaceuticals, Inc. (VGX) announced that the U.S. Food and Drug Administration (FDA) has approved the Company's Investigational New Drug (IND) application for its DNA vaccine for cervical cancer therapy, VGX-3100. The Company expects to initiate the Phase I clinical study for VGX-3100 in patients in a multi-center study in the third quarter of 2008. More information on this study is available

Gen-Probe Launches In Europe CE-Marked APTIMA(R) HPV Assay For Detection Of Human Papillomavirus
Gen-Probe Incorporated (Nasdaq: GPRO) announced that the Company has launched in Europe its APTIMA(R) HPV Assay, a highly specific molecular diagnostic test to detect high-risk strains of the human papillomavirus (HPV), which causes cervical cancer. The APTIMA HPV Assay has been CE marked and is currently available for sale in 13 European Union countries.

Gen-Probe Launches In Europe CE-Marked APTIMA(R) HPV Assay For Detection Of Human Papillomavirus
Gen-Probe Incorporated (Nasdaq: GPRO) announced that the Company has launched in Europe its APTIMA(R) HPV Assay, a highly specific molecular diagnostic test to detect high-risk strains of the human papillomavirus (HPV), which causes cervical cancer. The APTIMA HPV Assay has been CE marked and is currently available for sale in 13 European Union countries.

Merck, FDA Update Potential Adverse Reactions To HPV Vaccine Gardasil, Washington Times Reports
The Washington Times on Thursday reported that Merck and FDA last month added potential adverse reactions to Merck's human papillomavirus vaccine Gardasil to the package insert and information sheet given to patients.

Cervical Cancer Screenings Lacking In Developing Countries
A study published in the open-access journal PLoS Medicine has found that women in the developing world are not getting the cervical cancer screenings that they need. Researcher Emmanuela Gakidou (University of Washington, Seattle, USA) and colleagues report that although women in the developing world have the highest risk of developing cervical cancer, few are effectively screened.

Gen-Probe Launches In Europe CE-Marked APTIMA(R) HPV Assay For Detection Of Human Papillomavirus
Gen-Probe Incorporated (Nasdaq: GPRO) announced that the Company has launched in Europe its APTIMA(R) HPV Assay, a highly specific molecular diagnostic test to detect high-risk strains of the human papillomavirus (HPV), which causes cervical cancer. The APTIMA HPV Assay has been CE marked and is currently available for sale in 13 European Union countries.

Cervical Cancer Charity Welcomes Department Of Health's Announcement About HPV Vaccine, UK
The UK's leading cervical cancer charity, Jo's Trust, has welcomed the Department of Health's announcement that the HPV vaccine, Cervarix will be used in the national immunisation programme for 12/13 year olds starting in September, 2008.

Global Vaccine Alliance Board Approves $3.5B Investment Strategy That Includes HPV Vaccine
The board of the Global Alliance for Vaccines and Immunisation (GAVI) -- a public-private partnership that invests in childhood vaccinations in developing countries -- endorsed a $3.5 billion vaccine investment

Global Vaccine Alliance Board Approves $3.5B Investment Strategy That Includes HPV Vaccine
The board of the Global Alliance for Vaccines and Immunisation (GAVI) -- a public-private partnership that invests in childhood vaccinations in developing countries -- endorsed a $3.5 billion vaccine investment

HPV Testing Offers Women Protection For Twice As Long As Smear Testing
The long term findings of a study carried out at Hammersmith hospital reveal that testing for Human Papilloma Virus (HPV) can be twice as effective at protecting women from developing cervical abnormalities as smear testing. Results of the research - led by Professor Jack Cuzick of Barts and The London School of Medicine and Dentistry - are published in the International Journal of Cancer.

GSK Does Not Expect FDA Approval Of HPV Vaccine Cervarix Until End Of 2009
GlaxoSmithKline on Monday said it does not expect to receive FDA approval for its human papillomavirus vaccine Cervarix until late 2009, Reuters reports. GSK said it has decided to wait until results from a Phase III trial of the vaccine are available before seeking U.S. approval.

Cervarix?, GSK's Cervical Cancer Vaccine, Wins Tender For UK National Immunisation Programme
GlaxoSmithKline's (GSK) cervical cancer vaccine, Cervarix TM, was confirmed as the UK Department of Health's vaccine of choice for its national human papillomavirus (HPV) immunisation programme. The programme, which aims to protect against the two types of HPV that are responsible for approximately 70% of cervical cancers1, will start in September 2008 and will vaccinate girls aged 12 to 13 each year.

Cervical Cancer Screenings Lacking In Developing Countries
A study published in the open-access journal PLoS Medicine has found that women in the developing world are not getting the cervical cancer screenings that they need. Researcher Emmanuela Gakidou (University of Washington, Seattle, USA) and colleagues report that although women in the developing world have the highest risk of developing cervical cancer, few are effectively screened.

Privacy Policy for http://clinic-cervicalcancer.blogspot.com/

If you require any more information or have any questions about our privacy policy, please feel free to contact us by email at giv2emymon@gmail.com.

At http://clinic-cervicalcancer.blogspot.com/, the privacy of our visitors is of extreme importance to us. This privacy policy document outlines the types of personal information is received and collected by http://clinic-cervicalcancer.blogspot.com/ and how it is used.

Log Files
Like many other Web sites, http://clinic-cervicalcancer.blogspot.com/ makes use of log files. The information inside the log files includes internet protocol ( IP ) addresses, type of browser, Internet Service Provider ( ISP ), date/time stamp, referring/exit pages, and number of clicks to analyze trends, administer the site, track user’s movement around the site, and gather demographic information. IP addresses, and other such information are not linked to any information that is personally identifiable.

Cookies and Web Beacons
http://clinic-cervicalcancer.blogspot.com/ does use cookies to store information about visitors preferences, record user-specific information on which pages the user access or visit, customize Web page content based on visitors browser type or other information that the visitor sends via their browser.

Some of our advertising partners may use cookies and web beacons on our site. Our advertising partners include Google Adsense, .

These third-party ad servers or ad networks use technology to the advertisements and links that appear on http://clinic-cervicalcancer.blogspot.com/ send directly to your browsers. They automatically receive your IP address when this occurs. Other technologies ( such as cookies, JavaScript, or Web Beacons ) may also be used by the third-party ad networks to measure the effectiveness of their advertisements and / or to personalize the advertising content that you see.

http://clinic-cervicalcancer.blogspot.com/ has no access to or control over these cookies that are used by third-party advertisers.

You should consult the respective privacy policies of these third-party ad servers for more detailed information on their practices as well as for instructions about how to opt-out of certain practices. http://clinic-cervicalcancer.blogspot.com/'s privacy policy does not apply to, and we cannot control the activities of, such other advertisers or web sites.

If you wish to disable cookies, you may do so through your individual browser options. More detailed information about cookie management with specific web browsers can be found at the browsers' respective websites.

Department Of Health Awards Contract For HPV Vaccine
The contract to provide the vaccine against HPV (human papillomavirus), was awarded by the Department of Health to pharmaceutical company GlaxoSmithKline for their vaccine 'Cervarix'. The contract is to supply the vaccine that protects against cervical cancer and pre-cancerous cell changes in the cervix caused by HPV viruses.